

List of Study Group 2023-2024

2024

1. Kashiwagi H, Kuwana M, Murata M, Shimada N, Takafuta T, Yamanouchi J, et al. Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition Int J Hematol. 2024;119:1–13.
<https://link.springer.com/article/10.1007/s12185-023-03672-1>
2. Nogami K, Fujii T, Sawada A, Nagao A, Nagae C, Nojima M, et al. Association of physical activity with bleeding events and safety in patients with haemophilia A starting emicizumab prophylaxis: an interim analysis of the TSUBASA study Int J Hematol. 2024;119:14–23.
<https://link.springer.com/article/10.1007/s12185-023-03679-8>
3. Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, et al. Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11) Int J Hematol. 2024;119:24–38.
<https://link.springer.com/article/10.1007/s12185-023-03677-w>
4. Onishi A, Matsumura-Kimoto Y, Mizutani S, Isa R, Fujino T, Tsukamoto T, et al. Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma Int J Hematol. 2024;119:50–61.
<https://link.springer.com/article/10.1007/s12185-023-03680-1>
5. Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, et al. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11) Int J Hematol. 2024;119:130–45.
<https://link.springer.com/article/10.1007/s12185-023-03686-9>

6. Makita S, Ota S, Mishima Y, Usuki K, Ennishi D, Yanada M, et al. Japanese phase Ib study of the oral PI3K- δ and - γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma *Int J Hematol*. 2024;119:156–63.
<https://link.springer.com/article/10.1007/s12185-023-03689-6>
7. Fukunaga K, Ikegame K, Nakamae H, Doki N, Fukuda T, Kondo Y, et al. HLA haploidentical stem cell transplantation from HLA homozygous donors to HLA heterozygous donors may have lower survival rates than haploidentical transplantation from HLA heterozygous donors to HLA heterozygous donors: a retrospective nationwide analysis *Int J Hematol*. 2024;119:173–82.
<https://link.springer.com/article/10.1007/s12185-023-03693-w>
8. Minakata D, Uchida T, Nakano A, Takase K, Tsukada N, Kosugi H, et al. Characteristics and prognosis of patients with COVID-19 and hematological diseases in Japan: a cross-sectional study *Int J Hematol*. 2024;119:183–95.
<https://link.springer.com/article/10.1007/s12185-023-03685-w>
9. Kumano O, Suzuki S, Yamazaki M, An Y, Yasaka M, Ieko M, et al. Age-related variation in coagulation factors in non-valvular atrial fibrillation patients receiving direct oral anticoagulants *Int J Hematol*. 2024;119:407–15.
<https://link.springer.com/article/10.1007/s12185-024-03712-4>
10. Kawano N, Fukatsu M, Yamakawa K, Seki Y, Wada H, Okamoto K, et al. A systematic review and meta-analysis of recombinant human soluble thrombomodulin for the treatment of DIC associated with hematological malignancies *Int J Hematol*. 2024;119:416–25.
<https://link.springer.com/article/10.1007/s12185-023-03704-w>

11. Ogata M, Oshima K, Takano K, Kawano R, Ueda Y, Imamura T, et al. Effects of human herpesvirus 6B reactivation on cognitive function in cord blood transplant recipients: a prospective multicenter study *Int J Hematol.* 2024;119:432–41.
<https://link.springer.com/article/10.1007/s12185-024-03714-2>
12. Ueki H, Ogawa C, Goto H, Nishi M, Yamanaka J, Mochizuki S, et al. TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia *Int J Hematol.* 2024;119:450–8.
<https://link.springer.com/article/10.1007/s12185-024-03710-6>
13. Usuki K, Miyamoto T, Yamauchi T, Ando K, Ogawa Y, Onozawa M, et al. A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia *Int J Hematol.* 2024;119:647–59.
<https://link.springer.com/article/10.1007/s12185-024-03733-z>
14. Kato K, Izutsu K, Nishikori M, Shibayama H, Maeda Y, Yoshimura K, et al. End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial *Int J Hematol.* 2024;119: 677–85.
<https://link.springer.com/article/10.1007/s12185-024-03738-8>
15. Ide D, Fujino T, Kobayashi T, Egashira A, Miyashita A, Mizuhara K, et al. Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio *Int J Hematol.* 2024;119:697–706.
<https://link.springer.com/article/10.1007/s12185-024-03750-y>
16. Shibayama H, Itagaki M, Handa H, Yokoyama A, Saito A, Kosugi S, et al. Primary analysis of a prospective cohort study of

Japanese patients with plasma cell neoplasms in the novel drug era (2016–2021) *Int J Hematol.* 2024;119:707–21.

<https://link.springer.com/article/10.1007/s12185-024-03754-8>

17. Sano H, Fukushima K, Yano M, Osone S, Kato Y, Hasegawa D, et al. Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study *Int J Hematol.* 2024;119:745–54.
<https://link.springer.com/article/10.1007/s12185-024-03745-9>
18. Iriyama N, Iwanaga E, Kimura Y, Watanabe N, Ishikawa M, Nakayama H, et al. Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study *Int J Hematol.* 2024;120:60–70.
<https://link.springer.com/article/10.1007/s12185-024-03758-4>
19. Teshima T, Onishi Y, Kato K, Taniguchi S, Miyamura K, Fukushima K, et al. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial *Int J Hematol.* 2024;120:106–16.
<https://link.springer.com/article/10.1007/s12185-024-03772-6>
20. Tomomasa D, Tanita K, Hiruma Y, Hoshino A, Kudo K, Azumi S, et al. Highly sensitive detection of Epstein-Barr virus-infected cells by EBER flow FISH *Int J Hematol.* 2024;120:241–51.
<https://link.springer.com/article/10.1007/s12185-024-03786-0>
21. Minami Y, Doki N, Matsuoka H, Yokota T, Tomita A, Takahashi N, et al. Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study *Int J*

Hematol. 2024;120:305–13.

<https://link.springer.com/article/10.1007/s12185-024-03805-0>

22. Shimoda K, Komatsu N, Matsumura I, Ikeda K, Hino M, Hidaka M, et al. Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial Int J Hematol. 2024;120:314–24.
<https://link.springer.com/article/10.1007/s12185-024-03822-z>
23. Ohwada C, Sakaida E, Takeda Y, Doki N, Igarashi A, Onizuka M, et al. Survival impact of response within the first year in a multicenter prospective observational study of chronic GVHD in a Japanese cohort Int J Hematol. 2024;120:347–55.
<https://link.springer.com/article/10.1007/s12185-024-03813-0>
24. Ureshino H, Takahashi N, Ikezoe T, Kameoka Y, Kimura S, et al. A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial) Int J Hematol. 2024;120:492–500.
<https://link.springer.com/article/10.1007/s12185-024-03830-z>
25. Ito T, Kamimura T, Kiguchi T, Kato K, Takenaka R, Kobayashi M, et al. Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance Int J Hematol. 2024;120:613–20.
<https://link.springer.com/article/10.1007/s12185-024-03832-x>
26. Izutsu K, Ando K, Nishikori M, Shibayama H, Goto H, Kuroda J, et al. Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study Int J Hematol. 2024;120: 621–30.

<https://link.springer.com/article/10.1007/s12185-024-03834-9>

27. Goto H, Kada A, Ogawa C, Nishiuchi R, Yamanaka J, Iguchi A, et al. Treatment of relapsed acute lymphoblastic leukemia in children: an observational study of the Japan Children's Cancer Group Int J Hematol. 2024;120:631–8.
<https://link.springer.com/article/10.1007/s12185-024-03838-5>
28. Miyakawa Y, Sato E, Ogawa Y, Nishimura J, Nishimi M, Kawaguchi O, et al. Long-term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease Int J Hematol. 2024;120:656–64.
<https://link.springer.com/article/10.1007/s12185-024-03842-9>
29. Kirito K, Sugimoto Y, Gotoh A, Takenaka K, Ichii M, Inano T, et al. Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera Int J Hematol. 2024;120:675–83.
<https://link.springer.com/article/10.1007/s12185-024-03846-5>
30. Sugimoto Y, Nagaharu K, Ohya E, Ohishi K, Tawara I, Ito T, et al. Clinical characteristics in adolescents and young adults with polycythemia vera and essential thrombocythemia in Japan Int J Hematol. 2024;120:684–93.
<https://link.springer.com/article/10.1007/s12185-024-03862-5>
31. Shiratori S, Fukushima K, Onishi Y, Doki N, Goto T, Okada M, et al. Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study Int J Hematol. 2024;120:705–16.
<https://link.springer.com/article/10.1007/s12185-024-03850-9>
32. Shimonodan H, Sakaguchi K, Ishihara T, Okamoto Y, Nishikawa T, Keino D, et al. Silent inactivation of asparaginase in Japan:

results of the prospective ALL-ASP19 trial Int J Hematol. 2024;120:725–34.

<https://link.springer.com/article/10.1007/s12185-024-03856-3>

*****2023*****

1. Sekiguchi N, Kasahara S, Miyamoto T, Kiguchi T, Ohno H, Takagi T, et al. Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia. 2023;117:68-77.
<https://link.springer.com/article/10.1007/s12185-022-03464-z>
2. Leiva O, Ren S, Neuberg D, Bhatt A, Jenkins A, Rosovsky R, et al. Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease. Int J Hematol. 2023;117:90-9.
<https://link.springer.com/article/10.1007/s12185-022-03454-1>
3. Fukuhara N, Maruyama D, Hatake K, Nagai H, Makita S, Kamezaki K, et al. Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study. Int J Hematol. 2023;117:100-9.
<https://link.springer.com/article/10.1007/s12185-022-03455-0>
4. Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, et al. Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study. Int J Hematol. 2023;117:206-15.
<https://link.springer.com/article/10.1007/s12185-022-03473-y>

5. Fukuhara N, Kato K, Goto H, Takeshi T, Kawaguchi M, Tokushige K, et al. Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial. *Int J Hematol.* 2023;117:251-9.
<https://link.springer.com/article/10.1007/s12185-022-03481-y>
6. Nakamura Y, Mori T, Kako S, Yamazaki H, Kanda Y, Uchida N, et al. Outcome of peripheral blood stem cell transplantation from HLA-identical sibling donors for adult patients with aplastic anemia. *Int J Hematol.* 2023;117:356-65.
<https://link.springer.com/article/10.1007/s12185-022-03487-6>
7. Miyakawa Y, Imada K, Ichikawa S, Uchiyama H, Ueda Y, Yonezawa A, et al. The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study. *Int J Hematol.* 2023;117:366-77.
<https://link.springer.com/article/10.1007/s12185-022-03495-6>
8. Chang C-Y, Lai S-W, Cheng M-M, Ku J-T, Hu S-H, Liu Y-L, et al. Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIII-Fc prophylaxis therapy. *Int J Hematol.* 2023;117:378-87.
<https://link.springer.com/article/10.1007/s12185-022-03503-9>
9. Yanada M, Yamasaki S, Konuma T, Mizuno S, Uchida N, Onai D, et al. Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia. *Int J Hematol.* 2023;117:398-408.
<https://link.springer.com/article/10.1007/s12185-022-03486-7>

10. Kato K, Fujii N, Makita S, Goto H, Kanda J, Shimada K, et al. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis. *Int J Hematol.* 2023;117:409-20.
<https://link.springer.com/article/10.1007/s12185-022-03494-7>
11. Yanagisawa R, Hirakawa T, Doki N, Ikegame K, Matsuoka K, Fukuda T, et al. Severe short-term adverse events in related bone marrow or peripheral blood stem cell donors. *Int J Hematol.* 2023;117:421-7.
<https://link.springer.com/article/10.1007/s12185-022-03489-4>
12. Yoshida S, Onozawa M, Miyashita N, Kimura H, Takahashi S, Yokoyama S, et al. Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia. *Int J Hematol.* 2023;117:544-52.
<https://link.springer.com/article/10.1007/s12185-022-03522-6>
13. Munakata W, Ando K, Yokoyama M, Fukuhara N, Yamamoto K, Fukuhara S, et al. Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies. *Int J Hematol.* 2023;117:553-62.
<https://link.springer.com/article/10.1007/s12185-022-03514-6>
14. Shimomura Y, Kitamura T, Nishikubo M, Sobue T, Uchida N, Doki N, et al. Effect of the COVID-19 pandemic on allogeneic stem cell transplantation in Japan. *Int J Hematol.* 2023;117:590-7.
<https://link.springer.com/article/10.1007/s12185-022-03508-4>
15. Irie M, Niihori T, Nakano T, Suzuki T, Katayama S, Moriya K, et al. Reduced-intensity conditioning is effective for allogeneic hematopoietic stem cell transplantation in infants with *MECOM*-associated syndrome. *Int J Hematol.* 2023;117:598-606.

<https://link.springer.com/article/10.1007/s12185-022-03505-7>

16. Kanda Y, Usuki K, Inagaki M, Ohta A, Ogasawara Y, Obara N, et al. Decision analysis of allogeneic bone marrow transplantation versus immunosuppressive therapy for young adult patients with aplastic anemia. *Int J Hematol.* 2023;117:660–8.
<https://link.springer.com/article/10.1007/s12185-022-03530-6>
17. Yoshida C, Yamaguchi H, Doki N, Murai K, Iino M, Hatta Y, et al. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study *Int J Hematol.* 2023;117:694–705.
<https://link.springer.com/article/10.1007/s12185-023-03549-3>
18. Minakata D, Ishida T, Ando K, Suzuki R, Tanaka J, Hagiwara S, et al. Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma *Int J Hematol.* 2023;117:729–37.
<https://link.springer.com/article/10.1007/s12185-023-03538-6>
19. Onishi Y, Furukawa E, Kamata M, Fukatsu M, Kameoka Y, Hatta S, et al. Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL *Int J Hematol.* 2023;117:738–47.
<https://link.springer.com/article/10.1007/s12185-023-03546-6>
20. Shirai R, Osumi T, Keino D, Nakabayashi K, Uchiyama T, Sekiguchi M, et al. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma *Int J Hematol.* 2023;117:910–8.
<https://link.springer.com/article/10.1007/s12185-023-03566-2>
21. Miyashita N, Onozawa M, Yoshida S, Kimura H, Takahashi S, Yokoyama S, et al. Prognostic impact of FLT3-ITD, NPM1

mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study
Int J Hematol. 2023;118:36–46.

<https://link.springer.com/article/10.1007/s12185-023-03567-1>

22. Imai C, Sato A, Hiwatari M, Shimomura Y, Hori T, Suenobu S, et al. Outcomes following induction failure in Japanese children with acute lymphoblastic leukemia Int J Hematol. 2023;118:99–106.

<https://link.springer.com/article/10.1007/s12185-023-03600-3>

23. Morimoto A, Shioda Y, Kudo K, Kanegane H, Imamura T, Koh K, et al. Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 study Int J Hematol. 2023;118:107–18.

<https://link.springer.com/article/10.1007/s12185-023-03568-0>

24. Tokuhira M, Kimura Y, Tabayashi T, Watanabe N, Tsuchiya S, Takaku T, et al. Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects Int J Hematol. 2023;118:210–20.

<https://link.springer.com/article/10.1007/s12185-023-03606-x>

25. Fujii N, Onizuka M, Fukuda T, Ikegame K, Kawakita T, Nakamae H, et al. Clinical characteristics of late-onset interstitial pneumonia after allogeneic hematopoietic stem cell transplantation Int J Hematol. 2023;118:242–51.

<https://link.springer.com/article/10.1007/s12185-023-03624-9>

26. Miyagawa N, Goto H, Ogawa A, Kikuta A, Kosaka Y, Sekimizu M, et al. Phase 2 study of combination chemotherapy with

bortezomib in children with relapsed and refractory acute lymphoblastic leukemia Int J Hematol. 2023;118:267–76.

<https://link.springer.com/article/10.1007/s12185-023-03609-8>

27. Usuki K, Ikezoe T, Ishiyama K, Kanda Y, Gotoh A, Hayashi H, et al. Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan Int J Hematol. 2023;118:311–22.
<https://link.springer.com/article/10.1007/s12185-023-03625-8>
28. Okamoto H, Inoue Y, Miyashita A, Kawaji-Kanayama Y, Chinen S, Fujino T, et al. Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system Int J Hematol. 2023;118:323–32.
<https://link.springer.com/article/10.1007/s12185-023-03627-6>
29. Yano M, Ishida H, Hara J, Kawaguchi H, Ito E, Moriya-Saito A, et al. Outcome of hematopoietic stem cell transplantation in pediatric patients with acute lymphoblastic leukemia not in remission enrolled in JACLS ALL-02 Int J Hematol. 2023;118:364–73.
<https://link.springer.com/article/10.1007/s12185-023-03626-7>
30. Fuchida S, Ogura M, Ishida T, Hata H, Handa H, Katoh N, et al. A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research Committee Int J Hematol. 2023;118:443–9.
<https://link.springer.com/article/10.1007/s12185-023-03647-2>
31. Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, et al. Measurable residual disease in Japanese patients with

relapsed or refractory chronic lymphocytic leukemia treated with venetoclax *Int J Hematol.* 2023;118:526–8.

<https://link.springer.com/article/10.1007/s12185-023-03646-3>

32. Matsumoto M, Miyakawa Y, Kokame K, Ueda Y, Wada H, Higasa S, et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023 *Int J Hematol.* 2023;118: 529–546.

<https://link.springer.com/article/10.1007/s12185-023-03657-0>

33. Kawada J, Ito Y, Ohshima K, Yamada M, Kataoka S, Muramatsu H, et al. Updated guidelines for chronic active Epstein–Barr virus disease *Int J Hematol.* 2023;118:568–76.

<https://link.springer.com/article/10.1007/s12185-023-03660-5>

34. Stuckey R, Ianotto J, Santoro M, Czyż A, Perez Encinas MM, Gómez-Casares MT, et al. Prediction of major bleeding events in 1381 patients with essential thrombocythemia *Int J Hematol.* 2023;118:589–95.

<https://link.springer.com/article/10.1007/s12185-023-03650-7>

35. Shimura Y, Shibayama H, Nakaya A, Yamamura R, Imada K, Kaneko H, et al. Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum *Int J Hematol.* 2023;118:609–17.

<https://link.springer.com/article/10.1007/s12185-023-03653-4>